ANPMF Andean Precious Metals Corporation (QX)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2013

Angiotech Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

1618 Station Street, Vancouver, BC, Canada V6A 1B6

(Address of principal executive offices)

(604) 221-7676

(Registrant’s Telephone Number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On March 18, 2013, Angiotech Pharmaceuticals, Inc., a corporation organized under the laws of British Columbia  (“Angiotech” or the “Company”), announced that, Deutsche Bank National Trust Company as trustee (the “Trustee”) under the Indenture (as defined below), issued a notice of redemption, filed herewith as Exhibit 99.1 and incorporated herein by this reference, to the record holder of the Company’s Senior Secured Floating Rate Notes due 2013 (the “Notes”, CUSIP Number 034918AH5) on behalf of Angiotech to redeem $16.0 million in aggregate principal amount of the Notes.  The redemption price for the Notes is equal to 100% of principal amount of the Notes, together with any accrued and unpaid interest on the principal amount of the Notes to, but excluding, the redemption date, which is April 17, 2013.  On the redemption date, the redemption price for the Notes will become due and payable.  As of the date hereof, there are approximately $60.0 million in aggregate principal amount of Notes outstanding.

The Company issued the Notes under that certain Indenture dated as of May 12, 2011, by and among the Company, as issuer, certain subsidiaries of the Company as guarantors referred to therein and the Trustee, as supplemented by that certain Supplemental Indenture, dated as of August 13, 2012, among the Company, the guarantors referred to therein, and the Trustee (the indenture, as supplemented, referred to as the “Indenture”). The redemption will be made pursuant to the terms of the Indenture.

On March 18, 2013, Angiotech issued a press release announcing the partial redemption of the Notes. A copy of Angiotech’s press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

(d) Exhibits. The following exhibits are filed herewith:

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3

EXHIBIT INDEX

4